An advisory panel recommended Thursday that the US Food and Drug Administration approve the extension of the use of a fish oil-derived drug to reduce the likelihood of heart attack and stroke in high-risk patients.
The panel of outside advisors voted 16 to 0 to enlarge the approved use of the drug, called Vascepa, from Amarin PLC. The FDA is not bound to follow the advice of its advisory committee, but it usually does.
The …
Source link
